Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Jourdan

Showing results (21-30 of 83) with videos related to

Pageof 9
Sort By:
American Journal of Blood Research|July 11, 2017
Erratum: Efficacy and safety of ClairYg®, a ready-to-use intravenous immunoglobulin, in adult patients with primary immune thrombocytopeniaBorhane Slama, Olivier Fain, Hervé Maisonneuve, et al.
Blood|January 13, 2004
Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemiaMohamad Mohty, Eric Jourdan, Naira Ben Mami, et al.
Ejhaem|August 21, 2023
Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practiceShanti Amé, Fiorenza Barraco, Jean-Christophe Ianotto, et al.
Molecular Cancer Therapeutics|November 4, 2010
Exon 7 deletion in the bcr-abl gene is frequent in chronic myeloid leukemia patients and is not correlated with resistance against imatinibJean-Baptiste Gaillard, Cécile Arnould, Sophie Bravo, et al.
International Journal of Hematology|September 5, 2003
Survival and proliferation factors of normal and malignant plasma cellsBernard Klein, Karin Tarte, Michel Jourdan, et al.
Leukemia & Lymphoma|November 5, 2013
A multicenter phase II study of single-agent enzastaurin in previously treated multiple myelomaEric Jourdan, Veronique Leblond, Hervé Maisonneuve, et al.
Dermatology and Therapy|August 24, 2023
Natural Retinol Analogs Potentiate the Effects of Retinal on Aged and Photodamaged Skin: Results from In Vitro to Clinical StudiesAnthony Brown, Marta Furmanczyk, David Ramos, et al.
Blood|April 9, 2004
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasoneJérôme Moreaux, Eric Legouffe, Eric Jourdan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) studyBertrand Coiffier, Nicolas Mounier, Serge Bologna, et al.
Haematologica|November 21, 2007
Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial resultsArnaud Pigneux, Virginie Perreau, Eric Jourdan, et al.
Pageof 9

Showing results (21-30 of 83) with videos related to

Sort By:
Pageof 9
American Journal of Blood Research|July 11, 2017
Erratum: Efficacy and safety of ClairYg®, a ready-to-use intravenous immunoglobulin, in adult patients with primary immune thrombocytopeniaBorhane Slama, Olivier Fain, Hervé Maisonneuve, et al.
Blood|January 13, 2004
Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemiaMohamad Mohty, Eric Jourdan, Naira Ben Mami, et al.
Ejhaem|August 21, 2023
Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practiceShanti Amé, Fiorenza Barraco, Jean-Christophe Ianotto, et al.
Molecular Cancer Therapeutics|November 4, 2010
Exon 7 deletion in the bcr-abl gene is frequent in chronic myeloid leukemia patients and is not correlated with resistance against imatinibJean-Baptiste Gaillard, Cécile Arnould, Sophie Bravo, et al.
International Journal of Hematology|September 5, 2003
Survival and proliferation factors of normal and malignant plasma cellsBernard Klein, Karin Tarte, Michel Jourdan, et al.
Leukemia & Lymphoma|November 5, 2013
A multicenter phase II study of single-agent enzastaurin in previously treated multiple myelomaEric Jourdan, Veronique Leblond, Hervé Maisonneuve, et al.
Dermatology and Therapy|August 24, 2023
Natural Retinol Analogs Potentiate the Effects of Retinal on Aged and Photodamaged Skin: Results from In Vitro to Clinical StudiesAnthony Brown, Marta Furmanczyk, David Ramos, et al.
Blood|April 9, 2004
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasoneJérôme Moreaux, Eric Legouffe, Eric Jourdan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) studyBertrand Coiffier, Nicolas Mounier, Serge Bologna, et al.
Haematologica|November 21, 2007
Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial resultsArnaud Pigneux, Virginie Perreau, Eric Jourdan, et al.
Pageof 9